Pacira Pharma (NASDAQ: PCRX) announced the receipt of a Warning Letter (attached for reference) from the U.S. Food and Drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE